(Q38204541)

31 August 2017

Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes (English)

1 reference

31 August 2017

0 references

0 references

André J Scheen

1

1 reference

PubMed ID

24731666

31 August 2017

Luc F Van Gaal

series ordinal

2

1 reference

PubMed ID

24731666

31 August 2017

language of work or name

1 reference

19 February 2014

1 reference

The Lancet: Diabetes & Endocrinology

31 August 2017

1 reference

31 August 2017

2

1 reference

31 August 2017

11

1 reference

31 August 2017

911-922

1 reference

Health and economic burden of the projected obesity trends in the USA and the UK.

31 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

The worldwide epidemiology of type 2 diabetes mellitus--present and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Quantification of the effect of energy imbalance on bodyweight

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Mechanisms linking obesity to insulin resistance and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: treating "sick fat" through improving fat function with antidiabetes therapies

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Mechanisms linking obesity with cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Weight reduction in diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Managing type 2 diabetes: balancing HbA1c and body weight

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Weight beneficial treatments for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Management of type 2 diabetes: new and future developments in treatment

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Bariatric surgery for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Type II diabetic subjects lose less weight than their overweight nondiabetic spouses

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Less fat reduction per unit weight loss in type 2 diabetic compared with nondiabetic obese individuals completing a very-low-calorie diet program

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Current management strategies for coexisting diabetes mellitus and obesity

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

New options for the treatment of obesity and type 2 diabetes mellitus (narrative review)

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Sleep apnoea and metabolic dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Obesity, cardiometabolic syndrome, and chronic kidney disease: the weight of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Are obesity and anthropometry risk factors for diabetic retinopathy? The diabetes management project

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Cardiovascular autonomic dysfunction is associated with central obesity in persons with impaired glucose tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Type 2 diabetes across generations: from pathophysiology to prevention and management

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

The genetic and epigenetic basis of type 2 diabetes and obesity

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Obesity and type 2 diabetes: which patients are at risk?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Environmental pollutants and type 2 diabetes: a review of mechanisms that can disrupt beta cell function.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Effects of amylin on eating and adiposity

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

The role of leptin in the control of insulin-glucose axis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the Ameri

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Dietary sugars and body weight: systematic review and meta-analyses of randomised controlled trials and cohort studies

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

The effect of exercise on visceral adipose tissue in overweight adults: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Reduction of diabetes risk in routine clinical practice: are physical activity and nutrition interventions feasible and are the outcomes from reference trials replicable? A systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Association of an intensive lifestyle intervention with remission of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Long-term drug treatment for obesity: a systematic and clinical review

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Antiobesity pharmacotherapy in the management of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Novel approaches to the pharmacotherapy of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

New obesity agents: lorcaserin and phentermine/topiramate

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Obesity in Europe – does anybody care?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Evaluation of lorcaserin for the treatment of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

The importance of obesity in diabetes and its treatment with sibutramine

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Cardiovascular risk-benefit profile of sibutramine

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Orlistat: current status in clinical therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Phentermine and topiramate extended release (Qsymia™): first global approval.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Lorcaserin: a review of its use in chronic weight management

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

The role of pramlintide for weight loss

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Pramlintide and the treatment of diabetes: a review of the data since its introduction

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

A review of gliptins in 2011.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Cardiovascular effects of gliptins

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Cardiovascular biology of the incretin system

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Is there a place for incretin therapies in obesity and prediabetes?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Dapagliflozin: a review of its use in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Anti-obesity drugs: a review about their effects and their safety

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Hormone-based therapies in the regulation of fuel metabolism and body weight

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Potential therapies based on antidiabetic peptides

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

New pharmacological approaches for obesity management.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

The role of leptin in obesity and the potential for leptin replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Leptin therapy in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Metreleptin: first global approval

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Novel approaches to the treatment of obesity and type 2 diabetes mellitus: bioactive leptin-related synthetic peptide analogs

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Amylin and leptin activate overlapping signalling pathways in an additive manner in mouse GT1-7 hypothalamic, C₂C₁₂ muscle and AML12 liver cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

It takes two to tango: combined amylin/leptin agonism as a potential approach to obesity drug development

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Novel strategy for the use of leptin for obesity therapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

Emerging combinatorial hormone therapies for the treatment of obesity and T2DM.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970004-X

7 January 2021

10.1016/S2213-8587(14)70004-X

Identifiers

DOI

1 reference

31 August 2017

1 reference

PubMed ID

24731666